# Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids

> **NCT00284947** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 7 (actual)

## Conditions studied

- Kidney Transplantation
- Adverse Effects

## Interventions

- **DRUG:** basiliximab
- **DRUG:** MMF/EC-MPS
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT00284947
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284947, "Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00284947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*